Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

ProMIS Neurosciences Inc PMN

ProMIS Neurosciences Inc. is a development stage biotechnology company. The Company is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA), an alpha-synucleinopathy. Its proprietary target discovery engine applies a thermodynamic, computational discovery platform - ProMIS and Collective Coordinates - to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product portfolio includes PMN310 / Amyloid-beta, PMN267 / TDP-43, and PMN442 / Alpha-synuclein. The Company plans to investigate additional synucleinopathies, including Parkinson's disease (PD) and dementia with Lewy bodies (DLB). Its wholly owned subsidiary is ProMIS Neurosciences (US) Inc.


NDAQ:PMN - Post by User

Comment by Jumpinjackfaston Jan 13, 2022 11:04am
89 Views
Post# 34312723

RE:RE:RE:RE:RE:Aduhelm stimulation

RE:RE:RE:RE:RE:Aduhelm stimulation Yes , it's a 3 way stop sign with this USELESS company what is true answer probably the best was from Mackie in 2019 after Biogen stopped clinical trials exact wording was WASTE OF INVESTORS MONEY , and that PMN 310 would probably never make it to clinical trials , and look where we are at . Partnerships on the other Best In Class talk , the company this management team worked at Sanofi Genzyme just partnered with a Korean Biotech upstart for there Alpha- Synuclein antibodies for $75 million U.S.D. and 985 million Bio Bucks , Promis never is mentioned on any deals . The ex employees don't even list this scam company on there resumes , one ex is already in the limelight with there Phase 3 A.D. trails it was just released last week his salary and his first bonus . So where is this FSG group at with all in on What !!.
 
<< Previous
Bullboard Posts
Next >>